RPRX: Royalty Pharma Plc
About
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Current Value
$26.091 Year Return
Current Value
$26.091 Year Return
Key Details
Market Cap
$11.56B
P/E Ratio
10.17
1Y Stock Return
-3.67%
1Y Revenue Growth
-2.52%
Dividend Yield
2.85%
Price to Book
1.7
Strategies that include RPRX
Stock's related to RPRX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NJR | 46.28% | $4.83B | +16.85% | 3.54% |
| EXC | 43.31% | $39.29B | +0.57% | 3.88% |
| AEE | 41.52% | $24.59B | +20.10% | 2.87% |
| YORW | 41.34% | $514.17M | -3.87% | 2.37% |
| POR | 41.19% | $4.95B | +14.95% | 4.16% |
| BNL | 40.55% | $3.21B | +9.29% | 6.76% |
| TU | 40.22% | $23.25B | -11.88% | 7.27% |
| AVA | 39.91% | $3.07B | +11.83% | 3.68% |
| AWR | 39.52% | $3.22B | +7.55% | 2.09% |
| SJW | 39.26% | $1.83B | -14.15% | 2.89% |
| NTST | 38.95% | $1.30B | +2.31% | 5.22% |
| SW | 38.84% | $13.78B | +15.02% | 1.14% |
| KELYA | 38.68% | $504.23M | -32.54% | 2.14% |
| EPR | 38.46% | $3.38B | -0.51% | 7.62% |
| CWT | 38.24% | $3.06B | +2.67% | 2.17% |
| NWE | 38.17% | $3.41B | +10.00% | 4.68% |
| BRX | 38.14% | $8.97B | +39.65% | 3.68% |
| OGN | 38.04% | $3.76B | +32.28% | 7.69% |
| IDA | 37.87% | $6.27B | +21.37% | 2.85% |
| GTY | 37.69% | $1.81B | +13.14% | 5.51% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SKYW | -0.04% | $4.43B | +136.32% | 0.00% |
| LTM | -0.04% | $8.51B | -100.00% | <0.01% |
| HCC | -0.11% | $3.58B | +27.38% | 0.47% |
| CATX | 0.12% | $458.24M | +162.59% | 0.00% |
| CRUS | -0.24% | $5.34B | +32.92% | 0.00% |
| ITCI | 0.26% | $8.84B | +42.41% | 0.00% |
| KVYO | -0.28% | $9.29B | +24.95% | 0.00% |
| ATI | 0.35% | $8.31B | +32.37% | 0.00% |
| AVAV | -0.35% | $5.50B | +51.29% | 0.00% |
| SPR | -0.35% | $3.72B | +23.27% | 0.00% |
| OCX | -0.41% | $42.93M | -36.09% | 0.00% |
| MESO | 0.44% | $1.23B | +347.11% | 0.00% |
| NHTC | 0.45% | $61.83M | +0.19% | 14.81% |
| SPOT | 0.46% | $90.80B | +159.59% | 0.00% |
| MTSI | 0.58% | $9.07B | +51.32% | 0.00% |
| ON | 0.59% | $28.38B | -2.54% | 0.00% |
| PRPH | -0.60% | $18.14M | -82.61% | 0.00% |
| PSN | 0.61% | $10.03B | +50.06% | 0.00% |
| USAP | 0.63% | $412.06M | +176.63% | 0.00% |
| GGAL | -0.64% | $6.81B | +291.69% | 0.50% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FN | -18.44% | $9.02B | +50.13% | 0.00% |
| HUSA | -16.41% | $16.69M | -11.56% | 0.00% |
| DELL | -16.22% | $99.00B | +84.60% | 1.24% |
| ARM | -15.70% | $139.85B | +126.83% | 0.00% |
| PSTG | -14.53% | $16.35B | +36.41% | 0.00% |
| NVMI | -14.20% | $5.16B | +44.02% | 0.00% |
| PANW | -13.46% | $126.99B | +46.98% | 0.00% |
| TEN | -13.25% | $606.64M | +3.32% | 4.39% |
| CDNS | -13.21% | $82.18B | +10.81% | 0.00% |
| AVGO | -12.60% | $772.28B | +68.52% | 9.87% |
| CAMT | -12.56% | $3.40B | +16.39% | 0.00% |
| BVN | -11.93% | $3.16B | +37.49% | 0.00% |
| SNPS | -11.89% | $82.03B | -1.18% | 0.00% |
| NFLX | -11.32% | $372.45B | +83.46% | 0.00% |
| RMBS | -11.25% | $5.57B | -21.87% | 0.00% |
| NVDA | -11.16% | $3.61T | +194.35% | 0.07% |
| TRMD | -11.00% | $2.31B | -24.74% | 25.24% |
| LQDA | -10.33% | $859.91M | +53.94% | 0.00% |
| COST | -10.22% | $412.13B | +62.81% | 0.49% |
| ANET | -9.90% | $118.95B | +75.41% | 0.00% |
ETF's related to RPRX
News
SeekingAlpha
Uncover hidden gems in the stock market with the 'Undercovered Dozen' series featuring undervalued stocks with potential for growth and strong financials.
Yahoo
Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer FoundationThe Prize includes a charitable donation to further fund medical research NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken.
Yahoo
The market shrugged off Royalty Pharma plc's ( NASDAQ:RPRX ) solid earnings report. We think that investors might be...
Finnhub
REFINITIV STREETEVENTS EDITED TRANSCRIPT RPRX.OQ - Q3 2024 Royalty Pharma PLC Earnings Call EVENT DATE/TIME:...
Finnhub
REFINITIV STREETEVENTS EDITED TRANSCRIPT RPRX.OQ - Q3 2024 Royalty Pharma PLC Earnings Call EVENT DATE/TIME:...
SeekingAlpha
Stay up to date on dividend activity with our weekly summary for Dividend Champions, Contenders, and Challengers, including ex-dividend and pay dates.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.